Anhui Huaheng Biotechnology Co., Ltd. (688639.SS)
CNY 34.06
(-4.0%)
CNY 34.06
(-4.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 301.41 Million | 357.42 Million | 95.7 Million | 109.56 Million | 181.47 Million | 89.3 Million |
| Net Income | 446.59 Million | 319.34 Million | 168.23 Million | 121.1 Million | 126.37 Million | 75.5 Million |
| Depreciation & Amortization | 98.83 Million | 59.15 Million | 47.5 Million | 35.04 Million | 33.14 Million | 24.31 Million |
| Deferred income taxes | 8.67 Million | 6.1 Million | 7.53 Million | - | 3.08 Million | 3.88 Million |
| Stock-based compensation | 21.04 Million | 36.42 Million | 2.24 Million | - | - | 22.88 Million |
| Change in working capital | -272.62 Million | -56.62 Million | -120.88 Million | -52.66 Million | 16.05 Million | -40.01 Million |
| Other non-cash items | 4.09 Million | -6.97 Million | -8.92 Million | 6.09 Million | 5.89 Million | 29.5 Million |
| Investing Cash Flow | -1.12 Billion | -342 Million | -511.82 Million | -73.81 Million | -79.86 Million | -63.75 Million |
| Investments in PPE | -1.26 Billion | -456.34 Million | -180.63 Million | -72.63 Million | -81.72 Million | -63.39 Million |
| Acquisitions | 6.59 Million | -4.68 Million | 1.34 Million | - | 1.38 Million | 15.61 Thousand |
| Investment purchases | -72.4 Million | -53 Million | -345 Million | -2 Million | - | - |
| Sales/Maturities of investments | 202.86 Million | 168.62 Million | 5.81 Million | - | - | - |
| Other Investing Activities | 5.06 Million | 3.4 Million | 6.65 Million | 824.1 Thousand | 485.83 Thousand | -358.24 Thousand |
| Financing Cash Flow | 1.02 Billion | 6.45 Million | 476.97 Million | -21.07 Million | -108.89 Million | 5.03 Million |
| Debt repayment | -1.16 Billion | -51.05 Million | -90 Million | -86 Million | -85 Million | -55 Million |
| Dividends payments | -97.56 Million | -59.72 Million | -36.39 Million | -2.85 Million | -74.6 Million | -4.63 Million |
| Common Stock Repurchased | -38.04 Million | - | -550.96 Million | - | - | - |
| Common Stock Issuance | - | - | 550.96 Million | - | - | - |
| Other Financing Activities | -32.49 Million | 117.77 Million | 604.53 Million | 67.78 Million | 50.7 Million | 64.67 Million |
| Accounts receivables | -89.69 Million | -102.17 Million | -138.58 Million | -88.39 Million | 22.12 Million | -30.22 Million |
| Accounts payables | -18.08 Million | 75.28 Million | 86.88 Million | 88.39 Million | 11.26 Million | 5.3 Million |
| Inventory | -173.52 Million | -35.84 Million | -76.71 Million | 7.59 Million | -20.41 Million | -18.97 Million |
| Other working capital | 21.04 Million | 6.1 Million | 7.53 Million | -60.25 Million | 3.08 Million | -21.03 Million |
| Cash at beginning of period | 146.97 Million | 119.84 Million | 59.67 Million | 47.65 Million | 53.82 Million | 24 Million |
| Cash at end of period | 352.49 Million | 146.97 Million | 119.84 Million | 59.67 Million | 47.65 Million | 53.82 Million |
| Capital Expenditure | -1.26 Billion | -456.34 Million | -180.63 Million | -72.63 Million | -81.72 Million | -63.39 Million |
| Effect of forex changes on cash | 6.54 Million | 5.24 Million | -686.24 Thousand | -2.66 Million | 1.1 Million | -768.61 Thousand |
| Net cash flow / Change in cash | 205.52 Million | 27.12 Million | 60.17 Million | 12.01 Million | -6.17 Million | 29.81 Million |
| Free Cash Flow | -967.74 Million | -98.92 Million | -84.92 Million | 36.93 Million | 99.74 Million | 25.9 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | 74.85 Million | 86.57 Million | 129.11 Million | 446.59 Million | 128.71 Million |
| Depreciation & Amortization | - | 33.25 Million | - | 98.83 Million | 98.83 Million | -48.33 Million |
| Deferred income taxes | - | - | - | - | 8.67 Million | 100.55 Million |
| Stock-based compensation | - | 2.18 Million | - | 21.04 Million | 21.04 Million | -10.52 Million |
| Change in working capital | - | -25.01 Million | - | -242.17 Million | -272.62 Million | -41.87 Million |
| Other non-cash items | - | -43.78 Million | -189.98 Million | -54.34 Million | 4.09 Million | -18.05 Million |
| Investing Cash Flow | -188.94 Million | -244.13 Million | -198.32 Million | -352.23 Million | -1.12 Billion | -457.99 Million |
| Investments in PPE | -189.78 Million | -245.56 Million | -190.64 Million | -350.35 Million | -1.26 Billion | -440.53 Million |
| Acquisitions | - | 41.95 Thousand | 18.3 Thousand | 5.42 Million | 6.59 Million | 364.24 Thousand |
| Investment purchases | - | -2 Million | -6.1 Million | -23.18 Million | -72.4 Million | -26.81 Million |
| Sales/Maturities of investments | - | - | - | 19.39 Million | 202.86 Million | 10.18 Million |
| Other Investing Activities | 846.39 Thousand | 3.38 Million | -1.6 Million | -3.5 Million | 5.06 Million | -1.19 Million |
| Financing Cash Flow | 217.73 Million | 75.61 Million | 316.6 Million | 591.62 Million | 1.02 Billion | 293.12 Million |
| Debt repayment | -367.25 Million | -81.31 Million | -339.35 Million | -615.14 Million | -1.16 Billion | -6.47 Million |
| Dividends payments | -149.52 Million | -10.48 Million | -10.39 Million | -97.56 Million | -97.56 Million | -2.68 Million |
| Common Stock Repurchased | - | - | - | -38.04 Million | -38.04 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | 4.79 Million | -22.75 Million | -13.62 Million | -32.49 Million | 302.28 Million |
| Accounts receivables | - | -6.89 Million | - | -89.69 Million | -89.69 Million | -58.9 Million |
| Accounts payables | - | - | - | - | -18.08 Million | - |
| Inventory | - | -18.12 Million | - | -173.52 Million | -173.52 Million | 17.02 Million |
| Other working capital | - | - | - | 21.04 Million | 21.04 Million | - |
| Cash at beginning of period | 393.54 Million | 370.42 Million | 181.6 Million | 181.11 Million | 146.97 Million | 233.57 Million |
| Cash at end of period | 445.3 Million | 393.54 Million | 370.91 Million | 352.49 Million | 352.49 Million | 181.11 Million |
| Capital Expenditure | -189.78 Million | -245.56 Million | -190.64 Million | -350.35 Million | -1.26 Billion | -440.53 Million |
| Effect of forex changes on cash | 1.33 Million | 5.24 Million | 3.06 Million | 552.01 Thousand | 6.54 Million | 1.93 Million |
| Net cash flow / Change in cash | 51.76 Million | 23.11 Million | 189.3 Million | 171.37 Million | 205.52 Million | -52.46 Million |
| Free Cash Flow | -189.78 Million | -204.08 Million | -294.05 Million | -418.93 Million | -967.74 Million | -330.05 Million |
CGEN
300425
SYNGENE
0NNU
300248
CSNVF